The EMBRAVE Study
TM
for children with early-onset SCN2A Developmental and Epileptic Encephalopathies (DEE)
If you would like to be notified when the next phase of the EMBRAVE study is initiated, please schedule a call with our Nurse Patient Navigator.
About PRAX-222
PRAX-222 is an investigational antisense oligonucleotide (ASO) with the potential to be the first disease-modifying treatment for early-onset SCN2A Developmental and Epileptic Encephalopathy (DEE).
An ASO is a short, synthetic segment of genetic sequence designed to correct the malfunction in a specific gene. In animal studies, PRAX-222 was shown to significantly reduce seizures, normalize developmental curves and improve survival. By targeting the underlying genetic cause of disease, PRAX-222 has demonstrated potential to go beyond seizures to treating other symptoms of the disease.
Speak to a nurse about the EMBRAVE Study
To schedule call with a Praxis Nurse Patient Navigator:
1. Please review the consent below.
2. Once you click "Schedule a call" a calendar will open,
and you can select a day and time to speak with the EMBRAVE nurse navigator.